ACP
DMRA

Arcus Capital Partners’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Arcus Capital Partners’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19
Closed -$557 – 204
2022
Q4 		$557 Buy
+19
New +$788 ﹤0.01% 345

Other funds holding DMRA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Arcus Capital Partners's DMRA Position: Q1 2023 in Review

Arcus Capital Partners sold out of Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q1 2023, closing a stake of 19 shares — an estimated $557 sold.

Arcus Capital Partners first reported a position in DMRA in Q4 2022 and held it in 1 quarter. The position peaked at $557 in Q4 2022. 26 funds tracked by Wall St. Rank hold DMRA as of Q1 2023.

  • Arcus Capital Partners reported no remaining Damora Therapeutics, Inc. Ordinary Shares position as of Q1 2023 after selling out during the quarter.
  • Arcus Capital Partners sold 19 Damora Therapeutics, Inc. Ordinary Shares shares in Q1 2023, an estimated $557.
  • Arcus Capital Partners first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q4 2022 and held it in 1 quarter.
  • Arcus Capital Partners's Damora Therapeutics, Inc. Ordinary Shares position peaked at $557 in Q4 2022.
  • 26 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2023.

Based on Arcus Capital Partners's 13F filing for Q1 2023, filed 9 May 2023.